Vicore announces the Nomination Committee for the 2024 Annual General Meeting
Stockholm, October 31, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has appointed the Nomination Committee for the 2024 Annual General Meeting. The three largest shareholders as of August 31, 2023 have been each appointed a member to the Nomination Committee, in accordance with the decision taken at the Annual General Meeting on May 11, 2021.
The Nomination Committee consists of Staffan Lindstrand, appointed by HealthCap VII L.P., Jan Särlvik, appointed by the Fourth Swedish National Pension Fund, and Ivo Staijen, appointed by HBM Healthcare Investments (Cayman) Ltd. Vicore’s chairman, Jacob Gunterberg, is also a member and acts as the convener of the Committee.
The task of the Nomination Committee is to prepare and present proposals for the number of board members to be elected by the AGM, the election of a chairman and other members of the board, board fees, remuneration for committee work, election of a chairman to the Annual General Meeting, election of auditors, and auditors’ fees, and proposals for rules for the appointment of a nomination committee for the Annual General Meeting 2025.
The Annual General Meeting will take place on May 7, 2024. Shareholders who wish to submit their comments or submit proposals to the Nomination Committee may do so by March 8, 2024, by email to email@example.com or by letter to Vicore Pharma Holding AB (publ), Kornhamnstorg 53, 111 27 Stockholm. The Nomination Committee's proposal will be presented in the notice convening the AGM and on the company's website.
For further information, please contact:
Jacob Gunterberg Chairman of the Board
Phone: +46 70 975 10 15
This information was submitted for publication on October 31, 2023, at 09:00 CET.
About Vicore Pharma Holding AB (publ)
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drug candidates to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF. C21 is protected by US and European orphan drug designation. A variety of patents have been filed to provide further protection for C21, out to 2040 and onwards. Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. Using its unique expertise in the ATRAG biology Vicore is further fueling its pipeline with several new small molecule drug assets, with long patent life and for a variety of indications, some of which could be partnered while others may be taken to the market by Vicore. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.